A fellowship-trained foot and ankle surgeon with expertise in reconstruction, sports injuries, and limb salvage, Dr. Talisse brings advanced care to three South Metro Atlanta locations.
Read More
Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world
Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology
Click here to register
Company plans to file its Earnings Report on August 14, 2025 on Form 10-Q for the quarter ended June 30, 2025
Jaguar CEO Lisa Conte presenting August 20 at Emerging Growth Conference to provide updates on near-term catalysts; Click here to register
Read MoreManuscript accepted for publication in Frontiers in Pharmacology, "Oral Administration of Ketamir-2, a Novel Ketamine Analog, Attenuates Neuropathic Pain in Rodent Models via Selective NMDA Antagonism" details Ketamir-2's superior performance in two validated neuropathic pain models and supports advancement to Phase 2a clinical trials by year-end 2025.
Read More
MMJ BioPharma is taking its fight for FDA approved cannabis medicine directly to DEA Administrator Terry Cole, as President Trump signals openness to marijuana's medical benefits. After seven years of delays, MMJ is ready to launch clinical trials for Huntington's disease and Multiple Sclerosis- if the DEA finally issues its long overdue API Bulk manufacturing registration.
Read MoreMipletamig's 85% frontline AML remission rate and favorable safety profile drive APVO's differentiated CD3 portfolio expansion with APVO455, a Nectin-4 x CD3 bispecific for multiple solid tumor types
CD3 bispecific portfolio now includes three candidates - mipletamig (AML), APVO442 (prostate cancer), and newly added APVO455 - advancing a targeted, tumor-specific strategy uniquely engineered for safety, tumor specificity and clinical impact
Mipletamig, continues to outperform benchmarks, trial enrollment continues
$15.9 million raised in 2Q25, extending cash runway into late 4Q25
Read More
Trump said his administration will focus on research to unlock the medical uses of marijuana, and other priorities the marijuana industry has sought. However, will employees within the DEA continue trying to block President Trumps marijuana orders?
Read More
Terrance Cole's Choice: Reformer or Cover-Up Artist? New DEA Administrator Terrance Cole stands at a crossroads:
Break rank, clean house, and restore the DEA's marijuana research credibility by approving MMJ BioPharma's application.
Or protect the old guard's corruption-and go down as the next puppet in a failed prohibitionist machine.
Quotes From Inside the Agency Reveal Systemic Corruption, Regulatory Negligence, and Public Health Betrayal.
The DEA's war on cannabis research is not just a failure of policy-it's a failure of morality.
Read More-Debuting a "coming soon" campaign for tubeless Pivot patch pump
- Expects special 510(k) filing for Pivot product in October
- Will introduce first level of its gamified training application developed by Level Ex, developers of the Level One diabetes-management game
Read More
Advanced AI Solutions Provide Measurable Short-Term ROI, Strategic Decision-Making Benefits and Operational Improvements; New Survey Highlights Leading AI Healthcare Vendors Based on Client Satisfaction and Outcomes
Read MoreNew data from Eurofins Discovery show that Telomir-1 blocks enzymes that drive disease by turning off critical genes-highlighting its potential to treat cancer, autoimmune conditions, neurodegeneration, and metabolic disorders through epigenetic modulation.
Read More
Where Is the DEA? The Real Threat Isn't Research-It's Rotten Weed.
"This is the height of hypocrisy," said Duane Boise, CEO MMJ. "DEA bureaucrats are blocking clean cannabis grown in a DEA inspected cultivation facility, while contaminated products circulate freely under their watch. The agency has abandoned its duty to protect patients."
Read More
NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque psoriasis (PsO) submitted to U.S. FDA in July
ANTHEM Phase 2b trial data of icotrokinra in ulcerative colitis scheduled for an oral presentation at the 33rd United European Gastroenterology Week (UEGW) on October 7th
Phase 3 VERIFY trial data set of rusfertide in polycythemia vera (PV) presented during plenary session at ASCO; U.S. NDA filing on track for Q4
Cash, cash equivalents and marketable securities of $673.0 million as of June 30, 2025, anticipated to provide cash runway through at least end of 2028
Read More
Electromedical Technologies (OTC: EMED) outlines key financial restructuring milestones, upcoming product updates, and new strategic partnerships to drive sustainable growth in the pain management market.
Read More
